Madrigal Pharmaceuticals Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2017 | $-3.8M | $-3.8M | $2.0K | $602.0K |
| Jun 2017 | $-7.7M | $-7.8M | $123.0K | $676.0K |
| Sep 2017 | $-5.0M | $-5.0M | $0 | $1.0M |
| Dec 2017 | $-5.9M | $-5.9M | $0 | $947.0K |
| Mar 2018 | $-8.6M | $-8.6M | $1.0K | $1.2M |
| Jun 2018 | $-5.4M | $-5.4M | $0 | $2.2M |
| Sep 2018 | $-5.2M | $-5.3M | $13.0K | $5.0M |
| Dec 2018 | $-6.3M | $-6.3M | $8.0K | $5.1M |
| Mar 2019 | $-6.5M | $-6.5M | $41.0K | $6.0M |
| Jun 2019 | $-11.5M | $-11.5M | $-1.0K | $7.8M |
| Sep 2019 | $-11.3M | $-11.3M | $-2.0K | $5.0M |
| Dec 2019 | $-12.3M | $-12.4M | $134.0K | $4.0M |
| Mar 2020 | $-30.5M | $-30.8M | $314.0K | $4.8M |
| Jun 2020 | $-24.3M | $-24.3M | $7.0K | $5.7M |
| Sep 2020 | $-47.9M | $-47.9M | $3.0K | $5.1M |
| Dec 2020 | $-54.9M | $-55.0M | $10.0K | $5.1M |
| Mar 2021 | $-43.4M | $-43.5M | $44.0K | $6.1M |
| Jun 2021 | $-46.9M | $-46.9M | $2.0K | $8.2M |
| Sep 2021 | $-45.6M | $-45.6M | $50.0K | $6.2M |
| Dec 2021 | $-48.1M | $-48.2M | $113.0K | $6.4M |
| Mar 2022 | $-49.9M | $-50.0M | $52.0K | $7.5M |
| Jun 2022 | $-57.4M | $-57.5M | $103.0K | $7.9M |
| Sep 2022 | $-59.1M | $-59.1M | $33.0K | $8.1M |
| Dec 2022 | $-58.5M | $-58.5M | $29.0K | $8.1M |
| Mar 2023 | $-84.1M | $-84.1M | $35.0K | $11.3M |
| Jun 2023 | $-75.3M | $-75.4M | $69.0K | $11.0M |
| Sep 2023 | $-84.9M | $-85.3M | $339.0K | $12.7M |
| Dec 2023 | $-79.9M | $-81.0M | $1.0M | $14.9M |
| Mar 2024 | $-149.2M | $-149.5M | $357.0K | $19.9M |
| Jun 2024 | $-134.9M | $-135.1M | $131.0K | $24.4M |
| Sep 2024 | $-67.0M | $-67.8M | $779.0K | $17.9M |
| Dec 2024 | $-104.5M | $-104.7M | $195.0K | $17.7M |
| Mar 2025 | $-88.9M | $-88.9M | $0 | $20.9M |
| Jun 2025 | $-47.1M | $-47.1M | $0 | $25.2M |
| Sep 2025 | $79.9M | $79.0M | $857.0K | $26.3M |
| Dec 2025 | $-133.5M | $-133.1M | $-390.0K | $25.8M |
| Mar 2026 | $-167.4M | $-171.3M | $3.8M | $34.0M |
| Jun 2026 | $23.3M | $19.1M | $4.3M | $35.4M |